R&D channel feed

Am­gen gives first glimpse at PRMT5 in­hibitor, days af­ter Bris­tol My­ers put a $1B promise on the tar­get

Last year
Pharma

Pfiz­er lands FDA ap­proval for $6.7B ul­cer­a­tive col­i­tis drug, tak­ing on an­ti­bod­ies as an oral al­ter­na­tive

Last year
Pharma
FDA+

Cas­sa­va re­sponds to ac­cu­sa­tions of 'sci­en­tif­ic mis­con­duct,' re­it­er­ates sup­port of da­ta be­hind con­tro­ver­sial Alzheimer's drug

Last year

Most de­tailed hu­man brain map yet is ‘lay­ing the foun­da­tion for find­ing fu­ture cures’

Last year
In Focus

Ab­b­Vie and In­cyte re­port PhI­Ib vi­tili­go da­ta on oral JAKs an­a­lysts call ‘un­dif­fer­en­ti­at­ed’

Last year

Eli Lil­ly touts PhI­II mirik­izum­ab win in Crohn’s de­spite woes in oth­er con­di­tions

Last year

CRO at cen­ter of Pfiz­er’s Ly­me vac­cine study woes says FDA found no tri­al mis­con­duct 

Last year
Pharma
FDA+

eGe­n­e­sis brings kid­ney xeno­trans­plants clos­er to the clin­ic

Last year
Cell/Gene Tx

Mi­cro­bio­me start­up sells off as­sets; Faron's PhI/II da­ta in bone mar­row can­cer; AM Phar­ma touts bio­mark­er re­sults

Last year
News Briefing

Dan­ish biotech gears up for Phase IIb hidradeni­tis sup­pu­ra­ti­va tri­al fol­low­ing ear­ly clin­i­cal re­sults

Last year

Tem­pest eyes piv­otal tri­al for liv­er can­cer drug af­ter un­veil­ing ear­ly PFS, OS da­ta

Last year

No­vo stops late-stage kid­ney tri­al for semaglu­tide ear­ly for ef­fi­ca­cy, da­ta com­ing in 2024

Last year

Sana nar­rows fo­cus to ex vi­vo cell ther­a­pies, lays off 29% of staff to reach key clin­i­cal da­ta

Last year
People
Cell/Gene Tx

Mer­ck says Keytru­da im­proves sur­vival be­fore and af­ter lung can­cer surgery, awaits FDA de­ci­sion next week

Last year

Ven­tyx un­veils pos­i­tive PhII ul­cer­a­tive col­i­tis da­ta but stock is down 20% due to com­pet­i­tive space

Last year

Im­mu­nic touts PhII bio­mark­er da­ta for mul­ti­ple scle­ro­sis drug

Last year

Akero’s drug miss­es the mark in se­vere form of NASH

Last year

Anap­tys­Bio touts PhI­II win in a rare form of pso­ri­a­sis. But it does­n't plan on keep­ing the drug

Last year
Deals

Up­dat­ed: Two years on from con­fir­ma­to­ry tri­al halt, FDA sub­mits more ques­tions to On­copep­tides over Pepax­to with­draw­al

Last year
FDA+

Hamas strikes could im­pact some bio­phar­ma op­er­a­tions in Is­rael

Last year
Pharma

Scoop: No­var­tis ax­es mid-stage de­pres­sion tri­al of ke­t­a­mine-like in­jec­tion

Last year
Pharma

Ex­clu­sive: Ver­tex CSO David Alt­shuler talks non-opi­oid pain pills, AI and the myth of break­throughs

Last year
People

FDA re­jects Al­ny­lam’s On­pat­tro la­bel ex­pan­sion af­ter ad­comm vot­ed in fa­vor

Last year
Pharma
FDA+

The re­searchers who res­ur­rect­ed In­re­bic are test­ing a new bone mar­row can­cer drug in space

Last year
First page Previous page 68697071727374 Next page Last page
A service from the Financial Times